Home » FDA Accepts Dacogen sNDA Submission in Acute Myeloid Leukemia
FDA Accepts Dacogen sNDA Submission in Acute Myeloid Leukemia
SuperGen announced that Eisai released information that the FDA has accepted for review its supplemental New Drug Application (sNDA) seeking approval of Dacogen (decitabine) for injection in the treatment of acute myeloid leukemia.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May